Albany, NY -- (SBWIRE) -- 07/18/2019 -- Secondary Hyperparathyroidism Market Insights, Epidemiology and Market Forecast-2028

1. Chronic Kidney Disease is the most common cause of Secondary Hyperparathyroidism. 56.3% of the prevalent dialysis patients were males, as were 59.7% of the kidney transplant recipients in the USA.
2. Secondary Hyperparathyroidism prevalence among Chronic Kidney Disease patients in the United States is 54% while it is 43.8% in France.
3. Secondary Hyperparathyroidism prevalence among Chronic Kidney Disease patients in the EU5 countries was the lowest in Italy at 29.7%, preceded by Germany at 32.1%. France had the highest prevalence rate at 43.8%.

(Albany, US) DelveInsight launched a new report on Secondary Hyperparathyroidism Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Secondary Hyperparathyroidism market report covers a descriptive overview and comprehensive insight of the Secondary Hyperparathyroidism epidemiology and Secondary Hyperparathyroidism market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Secondary Hyperparathyroidism market report provides insights on the current and emerging therapies.
3. Secondary Hyperparathyroidism market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Secondary Hyperparathyroidism market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Secondary Hyperparathyroidism market.

Request for sample pages

"It was found that 60.4% of the diabetic patients and 65% of non-diabetic patients suffered from Secondary Hyperparathyroidism among a subject population of 409 patients."

Secondary Hyperparathyroidism therapeutic market can be segmented across three main verticals consisting of Vitamin D compounds (and its derivatives), Phosphate Binders and Calcimimetics. Vitamin D compounds; mainly comprises of calcitriol or its prodrug, alfacalcidol, doxercalciferol, 22-oxacalcitriol, or paricalcitol which help activate the VDRs (vitamin D receptors). Calcium free phosphate binders help reduce serum phosphate levels without any significant adverse effect on serum calcium and circulating PTH levels. Calcimimetics, on the other hand, are basically positive allosteric modulators of the CaSR (calcium-sensing receptor), which lead to increased sensitivity to extracellular calcium and subsequently to a decrease in circulating levels.

The pipeline is also filled with exciting new therapies and expanded trials of already approved drugs. Due to the emergence of the calcimimetics and a better understanding of the strengths and limitations of native and active vitamin D compounds, the treatment options for Secondary Hyperparathyroidism patients have improved. In view of this, the overall Secondary Hyperparathyroidism market sales are expected to show a positive growth during the forecast period [2018-2027].

Major players involved are:
1. Shire
2. Genzyme
3. Roche
4. Genzyme
5. Amgen
And many others

Drugs involved are-
1. Fosrenol
2. Renevela
3. Rayaldee
4. Rocaltrol
5. Hectorol
6. Sensipar
And many others
Table of contents

1. Report Introduction
2. Secondary Hyperparathyroidism Market Overview at a Glance
3. Secondary Hyperparathyroidism Disease Background and Overview
4. Secondary Hyperparathyroidism Epidemiology and Patient Population
5. Secondary Hyperparathyroidism Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Assumptions and Rationale
5.2.2.Germany
5.2.3.France
5.2.4.Italy
5.2.5.Spain
5.2.6.United Kingdom
5.3. Japan
6. Secondary Hyperparathyroidism Treatments & Medical Practices
7. Secondary Hyperparathyroidism Marketed Products
7.1. Rayaldee: Opko
8. Secondary Hyperparathyroidism Emerging Therapies
8.1. Key Cross Competition
8.2. SK-1403: Sanwa Kagaku Kenkyusho Co., Ltd.
9. Secondary Hyperparathyroidism Market Size
10. Secondary Hyperparathyroidism Country-Wise Market Analysis 7MM
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight